Ultragenyx Pharmaceutical RARE EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Ultragenyx Pharmaceutical’s reported figures.
Based on trailing twelve months.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's EBITDA margin?
- Ultragenyx Pharmaceutical (RARE) reported EBITDA margin of -78.7% in Q1 2026.
- How has Ultragenyx Pharmaceutical's EBITDA margin changed year-over-year?
- Ultragenyx Pharmaceutical's EBITDA margin increased by 2.7% year-over-year, from -80.9% to -78.7%.
- What is the long-term trend for Ultragenyx Pharmaceutical's EBITDA margin?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's EBITDA margin has grown at a -8.7% compound annual growth rate (CAGR), from -117.3% to -74.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.